Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Urinary Bladder Neoplasms 25Sarcoma 25Carcinoma, Renal Cell 25Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rhabdomyosarcoma, Alveolar × 90 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡